If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Review and Restructing

4 Dec 2006 16:08

Torex Retail PLC04 December 2006 TOREX RETAIL PLC ANNOUNCES PHASE TWO OF CORPORATE RESTRUCTURING TO INCREASE FOCUS ON CORE BUSINESSES THROUGH DISPOSAL OF NON CORE OPERATIONS AND DIRECTORSHIP CHANGES Torex Retail Plc ("Torex"), the leading international supplier of innovativecomputer systems to the retail sector, is pleased to announce the sale of noncore operations. A package of businesses, product lines, assets and distribution rightscomprising Leisure, Hotel and Digital Signage systems activities has been soldfor a maximum consideration of £8.0 million. The package of Non Core Operations have been sold to Shoo 291 Limited, a newcompany formed to effect the acquisitions by Ed Dayan and Mark Pearman who areboth Directors of Torex, but who will be stepping down from the Board withimmediate effect. These Non Core Operations are expected to achieve full yearrevenues of an estimated £6.5 million in 2006 and comprise a number of smallcompanies and businesses employing 65 people across the UK, US, South Africa ,Australia and Malaysia. Separately, Ace Casino Equipment Pty Limited, a South African subsidiaryoperating in the casino and gaming sector has been sold to Source IP Limited fora consideration of £1.8m. The combined effect of the divestments on full year revenues and operatingprofit is estimated at a reduction of £1.8m and £0.3m respectively. Thesebusiness units have a disproportionately high level of activity in the lastquarter of the year. The disposal increases the focus of the Group on its main markets in Retail,Hospitality, Quick Service Restaurants and Petroleum & Convenience freeing upvaluable management time and resources. Chris Moore, Chairman of Torex, commented: "The disposal of these small non core operations significantly sharpens thefocus of the Group both in terms of sector and geographic concentration. Due totheir small size and contribution the non core operations have not, and willnot, achieve their true potential in a large group like Torex. It is thereforeright for them to move forward under new ownership which will give them thefocus and investment they require. On behalf of the Board I would like to thank all the Torex employees who aretransferring to the new company for their hard work and dedication during theiremployment with our Group. The Board would like to thank Ed Dayan and Mark Pearman for their contributionto the development of the Group and we wish them and their new team everysuccess in their new venture." BOARD CHANGES In addition Torex confirms that arrangements have been made for restructuring ofthe Board. Chris Moore will remain on the Board as Non Executive Chairman untilsuch time as the company appoints a new independent Non Executive Chairman. Mr Moore has entered into a full time consultancy agreement with Torex for aminimum period of 12 months under which he will actively manage top level clientrelationships in certain major global accounts. A fixed term consultancy arrangement has also been agreed with Nigel Horn, LegalDirector and Company Secretary, who will leave the Board with immediate effect. Marcus Leek, Chief Finance Officer has been appointed Company Secretary pendinga permanent appointment. Chris Moore in his position as Non Executive Chairman and the Directors nowleaving Torex continue to hold substantial shareholdings and support thebusiness going forward. Neil Mitchell, Chief Executive Officer of Torex stated:- "Since my arrival as Chief Executive Officer of Torex Retail plc and as part ofmy strategic review, this re-focusing of the Group around core operations andDirectorship changes to streamline the Board are significant steps in enabling afresh perspective being brought by new management in aggressively growing thenew Torex Retail going forward. Trading remains in line with market guidanceand we expect to post further positive updates including information on newcontract wins in the near future." Enquiries:- R Neil W Mitchell Chief Executive OfficerMarcus Leek Chief Finance OfficerGavin Palmer Corporate Governance & Investor Relations ManagerTorex Retail Plc0870 300 6061 Ginny Pullbrook/Sebastian Hoyle/Freida Moore/Lucie HollowayCitigate Dewe Rogerson020 7638 9571 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Mar 20157:09 amRNSDermaPure gains Medicare coverage approval
5th Mar 20151:36 pmRNSIssue of equity and total voting rights
5th Mar 20151:18 pmRNSIssue of equity and total voting rights
5th Mar 201510:38 amRNSUK Patient has world's first OrthoPure XM implant
26th Feb 201510:43 amRNSResignation of Dr Alison Fielding
9th Feb 201512:05 pmRNSResult of General Meeting
4th Feb 201510:59 amRNSIssue of equity and total voting rights
22nd Jan 201511:13 amRNSResults of Placing
22nd Jan 20157:00 amRNSProposed placing of new Ordinary Shares
1st Dec 20149:45 amRNSHolding(s) in Company
28th Nov 20149:45 amRNSHolding(s) in Company
25th Nov 20148:15 amRNSNotice of allowance for US meniscus patent
5th Nov 20147:00 amRNSTissue Regenix gains Medicare and Medicaid Q code
29th Oct 20147:00 amRNSInterim Results
22nd Oct 20149:01 amRNSInterim Results and Capital Markets Day
20th Oct 201410:19 amRNSdCELL(R) presented at prestigious EACTS congress
17th Oct 20143:35 pmRNSInitial Clinical Trial Results
10th Sep 20149:00 amRNSdCELL® technology presented at Royal Society event
30th Jul 20147:00 amRNSUK meniscus clinical trial & DermaPure US updates
25th Jul 20147:00 amRNSTissue Regenix adds European bladder matrix patent
18th Jul 201411:11 amRNSIssue of equity and total voting rights
27th Jun 20143:06 pmRNSResult of AGM
12th Jun 20147:00 amRNSTissue Regenix announces launch of DermaPure in US
22nd May 20147:00 amRNSPreliminary Decision to Approve "Q" Code Request
20th May 20147:00 amRNSDeferred Annual Bonus Award
19th May 201410:21 amRNSAnnual Report & Accounts and Notice of AGM
19th May 20147:00 amRNSPreliminary results for year ended 31 January 2014
16th May 20141:00 pmRNSTissue Regenix adds US patent
12th May 201411:00 amRNSNotice of Preliminary Results
30th Apr 20145:14 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSTissue Regenix adds Chinese patent
24th Apr 20148:40 amRNSHolding(s) in Company
4th Feb 20143:03 pmRNSIssue of Share Options
31st Jan 20141:11 pmRNSHolding(s) in Company
14th Jan 20145:22 pmRNSIssue of equity and total voting rights
9th Jan 201411:11 amRNSIssue of equity and total voting rights
19th Dec 20137:00 amRNSTissue Regenix to attend JPMorgan Healthcare Event
12th Dec 20137:00 amRNSTissue Regenix signs US distribution agreements
22nd Nov 20137:00 amRNSDirector Share Purchase
29th Oct 20137:00 amRNSPresentation at Proactiveinvestors Forum in Dublin
28th Oct 20134:49 pmRNSDirector Share Purchase
21st Oct 20137:00 amRNSPublication of DermaPure UK trial results
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
14th Oct 20137:00 amRNSTissue Regenix USA successful technology transfer
8th Oct 20137:00 amRNSInterim Results for six months ended 31 July 2013
12th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Marketing
6th Aug 20139:41 amRNSHolding(s) in Company
5th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Operations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.